A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol (ACTFAST SWISS)

February 17, 2021 updated by: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin

The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

370

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
    • BE
      • Langenthal, BE, Switzerland
        • Pfizer Investigational Site
      • Thun, BE, Switzerland
        • Pfizer Investigational Site
    • BL
      • Binningen, BL, Switzerland
        • Pfizer Investigational Site
      • Liestal, BL, Switzerland
        • Pfizer Investigational Site
    • BS
      • Basel, BS, Switzerland
        • Pfizer Investigational Site
    • FR
      • Duedingen, FR, Switzerland
        • Pfizer Investigational Site
    • GE
      • Geneve, GE, Switzerland
        • Pfizer Investigational Site
      • Onex, GE, Switzerland
        • Pfizer Investigational Site
    • SZ
      • Pfaeffikon, SZ, Switzerland
        • Pfizer Investigational Site
      • Siebnen, SZ, Switzerland
        • Pfizer Investigational Site
    • TI
      • Lugano, TI, Switzerland
        • Pfizer Investigational Site
      • Malvaglia, TI, Switzerland
        • Pfizer Investigational Site
      • Melide, TI, Switzerland
        • Pfizer Investigational Site
      • Vezia, TI, Switzerland
        • Pfizer Investigational Site
    • VD
      • Ecublens, VD, Switzerland
        • Pfizer Investigational Site
      • Lausanne, VD, Switzerland
        • Pfizer Investigational Site
      • Prilly, VD, Switzerland
        • Pfizer Investigational Site
    • ZG
      • Unteraegeri, ZG, Switzerland
        • Pfizer Investigational Site
      • Zug, ZG, Switzerland
        • Pfizer Investigational Site
    • ZH
      • Zuerich, ZH, Switzerland
        • Pfizer Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
  • LDL-C < 6.0 mmol/l
  • Triglyceride level < 5.0 mmol/l.

Exclusion Criteria:

  • Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Secondary Outcome Measures

Outcome Measure
The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2005

Study Registration Dates

First Submitted

August 25, 2005

First Submitted That Met QC Criteria

August 25, 2005

First Posted (Estimate)

August 29, 2005

Study Record Updates

Last Update Posted (Actual)

February 18, 2021

Last Update Submitted That Met QC Criteria

February 17, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A2581089

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperlipidemia

Clinical Trials on Atorvastatin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe